Familial hypercholesterolemia (FH) is a silent but devastating genetic disease, responsible for up to 20% of heart attacks in people under 45 years old. Detecting it early can make the difference between a healthy life and a premature cardiovascular event.
This genetic test allows precise identification of the genetic variants involved in LDL cholesterol metabolism, distinguishing between monogenic and polygenic forms. This information not only improves diagnosis but also enables personalized treatment, cardiovascular risk stratification, and cascade screening in family members.
In a clinical environment increasingly focused on preventive and personalized medicine, this test becomes an essential tool for doctors and patients committed to effective cardiovascular disease prevention.